Immunotherapy of cancer by IL-12-based cytokine combinationsJonathan M. Weiss, Robert H. Wiltrout, Jeffrey Subleski et al.|Expert Opinion on Biological Therapy|2007Cited by 223
IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapyJon M. Wigginton, Robert H. Wiltrout, Lisa Geiselhart et al.|Journal of Clinical Investigation|2001Cited by 126
IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapyJon M. Wigginton, Robert H. Wiltrout, Eilene Gruys et al.|Journal of Clinical Investigation|2001Cited by 109